FDA Approves Brentuximab Vedotin with Lenalidomide and Rituximab for Relapsed or Refractory Large B-Cell Lymphoma By Ogkologos - March 27, 2025 683 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ECHELON-3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Oxaliplatin-Based Adjuvant Chemotherapy Shows Good Tolerance and Similar Time To Recurrence... April 4, 2024 Workout Wednesday – Leg Stretches Part 1 July 8, 2020 FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory Follicular... July 31, 2024 FDA Approves Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma June 24, 2022 Load more HOT NEWS Studies Test CAR T-Cell Therapies Designed to Overcome Key Limitations Countdown to 100,000 OncoLife Survivorship Care Plans: How it all started Introducing our new podcast for researchers Consensus on Conceptual Framework for Precision Cancer Medicine in Germany
